Precision medicine: how multiomics will shape the future of inflammatory bowel disease?

Curr Opin Gastroenterol. 2022 Jul 1;38(4):382-387.doi: 10.1097/MOG.0000000000000847.


Nienke Z Borren 1Ashwin N Ananthakrishnan 2


Author information

1Department of Gastroenterology & Hepatology, Erasmus University Medical Center, Rotterdam, the Netherlands.

2Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.


Purpose of review: In this article, we provide an overview of studies examining multiomic profiling in various clinical scenarios in the management of inflammatory bowel diseases (IBDs).

Recent findings: IBD arises as a result of an interplay between genetic, environmental, microbial and immunologic perturbations. The access to high throughput technology as well as the decrease in costs associated with such studies has led to a growing wealth of literature examining the utility of single or multiomic profiles in the management of IBD. Such studies have commonly examined the genome (and less frequently the epigenome), transcriptome, metabolome, proteome and the gut microbial metagenome in the context of overall IBD status or specific clinical scenarios, including the disease progression or response to treatment. The findings have provided important insight into how each of these compartments reflect underlying disease pathophysiologic processes and, in turn, can influence stratification of patients for clinical management.

Summary: Multiomic profiling in IBD has the potential to advance the field of personalized precision medicine in the management of IBDs.



© Copyright 2013-2024 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.